Dr. Mohammad H. Kazemi, MD

Dr. Kazemi practices at Lehigh Valley Hospital-Cedar Crest in Allentown, Pennsylvania, part of Thomas Jefferson University.

Dr. Kazemi's NPI, 1235556531, was assigned on March 25, 2014. Dr. Kazemi graduated from Tehran University of Medical Sciences School of Medicine in 2010. Dr. Kazemi holds Pennsylvania license MD479984.

Dr. Kazemi's primary practice is Lehigh Valley Hospital-Cedar Crest, at 1200 South Cedar Crest Boulevard, Allentown, PA 18103 in Lehigh County. The practice phone is (610) 402-8000.

Dr. Kazemi's primary practice is Lehigh Valley Hospital-Cedar Crest in Allentown, Pennsylvania, part of Thomas Jefferson University. Dr. Kazemi is also affiliated with St. Luke's University Hospital - Bethlehem Campus. The medical group on file is Lehigh Valley Physician Group (LVPG). Dmand AI also links Dr. Kazemi to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kazemi practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kazemi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kazemi is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Kazemi's licenses on file in 2 states: Pennsylvania and New Jersey.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer and lymphoma among the conditions Dr. Kazemi treats.

CMS data shows 541 Medicare services from Dr. Kazemi across 8 procedure codes in 2024, for 242 Medicare patients. Medicare paid $44,121 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 242 Medicare patients who saw Dr. Kazemi in 2024. The largest group is 65 to 74, with 112 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kazemi's median patient age at 64, with 58% women.

In 2024, Dr. Kazemi wrote 572 Medicare Part D claims for 109 patients. 69% of them were for generic drugs. CMS names the drug for 395 of them, across 17 drugs with 11 or more claims each, at $906,590 in total drug cost. In 2023, CMS named 309 claims across 14 drugs.

Dr. Kazemi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kazemi as offering telehealth.

Dmand AI links 12 papers to Dr. Kazemi, published from 2018 to 2025. 2020 was the busiest year, with 2. The most frequent topics are Immunity, Innate and Lymphocytes. Dr. Kazemi has published most often in Micromachines (Basel). Dr. Kazemi's most frequent co-authors are Aditi Shastri, MD, Stephen Y.p. Shen, MD and Omar I. Abdel-Wahab, MD.

CMS Open Payments shows 30 general payments to Dr. Kazemi from 10 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 85% of the total. Kite Pharma, Inc. paid the most, $9,293.

Dr. Kazemi graduated from Tehran University of Medical Sciences School of Medicine in 2010.

Dr. Kazemi is in network with 18 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.